2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 972

Outcome of the Scleroderma Population “at Risk” to Develop Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Study
Abstract Number: 973

Clinical Characterization of Patients with World Health Organization Group 2 Pulmonary Hypertension in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort
Abstract Number: 974

Diffuse Scleroderma, Male Sex, and Myopathy Are Associated with Severe Gastrointestinal Dysmotility in Scleroderma
Abstract Number: 975

Maintenance Therapy Improves Long-Term Outcomes in Patients with Primary Angiitis of the Central Nervous System
Abstract Number: 976

Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan
Abstract Number: 977

Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study
Abstract Number: 978

A Randomized Clinical Trial of CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with ANCA-Associated Vasculitis
Abstract Number: 979

A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Takayasu’s Arteritis
Abstract Number: 980

Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study
Abstract Number: 981

Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting
Abstract Number: 982

High Financial Strain, but Not Poverty or Lower Education, Increases the Risk of Incident Depression in Systemic Lupus Erythematosus (SLE)
Abstract Number: 983

Objectively Assessed Sedentary Behaviour and Light Physical Activity Are Associated with Long-Term Cardiovascular Risk in People Living with Rheumatoid Arthritis Independently of Moderate-to-Vigorous Physical Activity
Abstract Number: 984

Clinical Characteristics of Inflammatory Myopathies Associated with Cancer: A Report from the Remicam Registry
Abstract Number: 985

Effectiveness of a Web-Based Personalized Rheumatoid Arthritis Risk Tool with or without a Health Educator for Knowledge of RA Risk Factors
Abstract Number: 986

Sex-Specific Associations Between Improvement in Gait Mechanics and Improvement in Pain, Function, and Abductor Strength after Total Hip Arthroplasty

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].